BVMFHYPE3
Market cap1.89bUSD
Dec 20, Last price
18.18BRL
1D
5.39%
1Q
-33.43%
Jan 2017
-30.42%
IPO
126.68%
Name
Hypera SA
Chart & Performance
Profile
Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, MaxSulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands. The company also provides dermo-cosmetics products under the Mantecorp Skincare brands; and consumer health products under the Apracur, Benegrip, Coristina d, Engov, Epocler, Estomazil, and other brands. In addition, it offers nutritional and vitamin supplement products under the Tamarine, Vitasay, Biotônico Fontoura, and Zero-Cal brands; and similar and generic medicines under the Neo Química, Sodium Diclofenac, Hydroxyzine, Dipyron, Ibuprofen, Losartan Potassium, Mal Dexchlorpheniramine, Naproxene, Paracetamol, Simethicon, Loratadine, Omeprazole, Tadalaphyl, and Desogestrel brand names. The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018. Hypera S.A. is based in São Paulo, Brazil.
Valuation
Title BRL in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | 2014‑12 | |
Income | ||||||||||
Revenues | 7,914,658 4.88% | 7,546,355 27.10% | 5,937,373 45.21% | |||||||
Cost of revenue | 4,864,608 | 4,797,214 | 3,809,652 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | 3,050,050 | 2,749,141 | 2,127,721 | |||||||
NOPBT Margin | 38.54% | 36.43% | 35.84% | |||||||
Operating Taxes | (141,638) | (95,348) | 26,580 | |||||||
Tax Rate | 1.25% | |||||||||
NOPAT | 3,191,688 | 2,844,489 | 2,101,141 | |||||||
Net income | 1,647,960 -2.87% | 1,696,697 27.55% | 1,330,208 2.71% | |||||||
Dividends | (759,885) | (806,208) | (745,936) | |||||||
Dividend yield | 3.36% | 2.90% | 4.13% | |||||||
Proceeds from repurchase of equity | (48,968) | (2,694) | (109,974) | |||||||
BB yield | 0.22% | 0.01% | 0.61% | |||||||
Debt | ||||||||||
Debt current | 2,140,996 | 2,298,757 | 602,488 | |||||||
Long-term debt | 8,188,010 | 7,590,623 | 6,803,883 | |||||||
Deferred revenue | ||||||||||
Other long-term liabilities | 376,409 | 405,280 | 404,082 | |||||||
Net debt | 7,627,474 | 6,895,190 | 5,008,308 | |||||||
Cash flow | ||||||||||
Cash from operating activities | 2,395,993 | 2,038,793 | 1,399,131 | |||||||
CAPEX | (814,778) | (1,509,456) | (838,882) | |||||||
Cash from investing activities | (791,188) | (1,742,337) | (4,412,425) | |||||||
Cash from financing activities | (1,886,385) | 278,955 | 557,058 | |||||||
FCF | 2,115,441 | 1,414,412 | 540,173 | |||||||
Balance | ||||||||||
Cash | 2,580,893 | 2,862,473 | 2,287,062 | |||||||
Long term investments | 120,639 | 131,717 | 111,001 | |||||||
Excess cash | 2,305,799 | 2,616,872 | 2,101,194 | |||||||
Stockholders' equity | 11,538,150 | 10,742,575 | 9,914,821 | |||||||
Invested Capital | 19,699,712 | 18,212,324 | 15,542,730 | |||||||
ROIC | 16.84% | 16.85% | 16.11% | |||||||
ROCE | 13.86% | 13.20% | 12.06% | |||||||
EV | ||||||||||
Common stock shares outstanding | 637,793 | 639,103 | 639,532 | |||||||
Price | 35.44 -18.40% | 43.43 53.63% | 28.27 -17.46% | |||||||
Market cap | 22,603,384 -18.56% | 27,756,243 53.52% | 18,079,570 -17.31% | |||||||
EV | 30,244,607 | 34,661,114 | 23,094,758 | |||||||
EBITDA | 3,288,362 | 2,918,242 | 2,261,407 | |||||||
EV/EBITDA | 9.20 | 11.88 | 10.21 | |||||||
Interest | 1,349,523 | 986,082 | 383,218 | |||||||
Interest/NOPBT | 44.25% | 35.87% | 18.01% |